Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021 2021-06-02 08:00
Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome 2021-05-28 08:00
Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development 2021-05-25 08:00
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037) 2021-05-17 20:35
Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial 2021-05-17 08:00
Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China 2021-05-14 08:40
Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies 2021-05-14 08:00
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer 2021-05-13 08:00
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines 2021-05-06 11:28
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment 2021-04-29 08:34
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL 2021-04-13 08:00
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations 2021-04-12 08:00
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma 2021-04-06 08:00
Antengene Announces Financial Results for Full Year 2020 2021-03-26 08:00
Antengene Appoints Kevin Lynch as Chief Medical Officer 2021-03-25 23:26
Antengene Appoints Bo Shan as Chief Scientific Officer 2021-03-25 22:36
Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021 2021-03-22 08:00
Antengene Included in the Shenzhen-Hong Kong Stock Connect 2021-03-15 09:40
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea 2021-03-15 08:00
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index 2021-03-01 08:00
1 3 4 5 6 7